Eli Lilly & Co
NYSE: LLY
$1124.37
+0.46
(+0.04%)
as on
Eli Lilly & Co Stock Performance
as on September 10, 2026 at 6:59 am IST
Day's Low
Day's High
$1,119.00$1,138.79
0.48%
Downside
1.28%
Upside
52 Week's Low
52 Week's High
$712.05$1,292.6536.67%
Downside
14.97%
Upside
Eli Lilly & Co share price movements today
- Previous Close
- $1,123.91
- Open
- $1,130.49
- Volume
- 1.1M
- Market Cap
- $1.1T
- Dividend Yield
- 0.60%
- Day's Low - High
- $1,119.00 - $1,138.79
- 52 Week Low - High
- $712.05 - $1,292.65
Eli Lilly & Co Historical Returns
- 1 Month Return
- -5.21 %
- 3 Month Return
- -1.81 %
- 1 Year Return
- + 49.73 %
- 3 Year Return
- + 91.64 %
- 5 Year Return
- + 368.3 %
Eli Lilly & Co Stock Fundamentals & Key Indicators
Check Eli Lilly & Co market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$1.1T
EPS (TTM)
29.85
Dividend Yield
0.60%
Quarterly Earnings Growth YOY
0.26%
PE Ratio (TTM)
37.65
Industry PE ratio
22.90
PEG Ratio
0.39910825348273427
EBITDA
35.2B
Revenue (TTM)
79.7B
Profit Margin
84.01%
Return On Equity TTM
92.58%
Eli Lilly & Co Stock Valuation
Track how Eli Lilly & Co P/E has moved over time to understand its valuation trends.
Eli Lilly & Co in the last 5 years
Lowest (46.73x)
December 31, 2025
Industry (22.90x)
December 31, 2025
Today (46.73x)
December 31, 2025
Highest (100.04x)
December 31, 2023
Today’s Price to Earnings Ratio: 46.73x
Eli Lilly & Co vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Eli Lilly & Co with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % | Dividend Yield % |
|---|---|---|---|---|---|---|
| BUY | $1.1T | 368.3% | 37.65 | 84.01% | 0.6% | |
| BUY | $663.3B | 60.12% | 31.11 | 70.45% | 1.96% | |
| HOLD | $162.2B | -39.63% | 35.41 | 71.32% | 6.419999999999999% |
Stock Returns calculator for Eli Lilly & Co Stock including INR - Dollar returns
The Eli Lilly & Co stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.
Investment Value
₹1,00,000
Eli Lilly & Co investment value today
Current value as on today
₹1,61,433
Returns
₹61,433
(+61.43%)
Returns from Eli Lilly & Co Stock
₹49,794 (+49.79%)
Dollar Impact
₹11,639 (+11.64%)
Analyst Recommendation on Eli Lilly & Co Stock
Based on 20 analysts
90.00%
Buy
10.00%
Hold
0.00%
Sell
Based on 20 analysts, 90% of analysts recommend a 'BUY' rating for Eli Lilly & Co. Average target price of $1315.56
Eli Lilly & Co Share Price Target
Get share price movements and forecasts by analysts on Eli Lilly & Co.
What analysts predicted
14.53%UPSIDE
Target Price
$1315.56
Current Price
$1124.37
Analyzed by
20 Analysts
Target
$1315.56
Eli Lilly & Co target price $1315.56, a slight upside of 14.53% compared to current price of $1124.37. According to 20 analysts rating.
Indian Investors' Interest in Eli Lilly & Co Stock
Investment in Eli Lilly & Co Shares on INDmoney has dropped by -10.66% in the last 30 days, indicating reduced investment activity.
Time period: to
Search interest for Eli Lilly & Co Stock has decreased by -6% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
Eli Lilly & Co Quarterly Profit & Loss
All numbers in Millions USD
Eli Lilly & Co Annual Profit & Loss
All numbers in Millions USD
Eli Lilly & Co Quarterly Cash Flow
All numbers in Millions USD
Eli Lilly & Co Annual Cash Flow
All numbers in Millions USD
Eli Lilly & Co News & Key Events
Today's Timeline - 09 September
Thu, 00:42 AM
-Eli Lilly's Q2 revenue surged 48% to $23 billion, raising 2026 revenue guidance to $85-$87 billion.
Thu, 02:13 AM
-Eli Lilly's shares outperform industry; strong demand for GLP-1 drugs drives growth despite pricing pressures.
Insights on Eli Lilly & Co
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Eli Lilly & Co. has shown strong revenue growth over the last six quarters, with revenue increasing from $12.72 billion to $22.97 billion. This represents an average quarterly growth rate of 11.0%.
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, LLY has outperformed top 5 stocks with highest market-cap in its industry
- POSITIVE IMPACT
Price Rise
In the last 1 year, LLY stock has moved up by 48.9%
NO EFFECTAgainst Peers
In the last 1 year, Johnson & Johnson has given 53.1% return, outperforming this stock by 4.2%
NEGATIVE IMPACTProfit Down
Eli Lilly & Co. has experienced a decline in net profit over the last two quarters. Specifically, their net profit fell from $7.39 billion to $7.09 billion, representing an average decrease of 4.1% per quarter.
About Eli Lilly & Co
Eli Lilly develops and sells medicines for diabetes, obesity, cancer, immunology, neuroscience and other diseases. Its portfolio combines large commercial products with a broad research pipeline. Eli Lilly's portfolio spans diabetes, obesity, cancer and other diseases, but current growth depends heavily on scaling supply for its leading metabolic medicines. Commercial performance depends on access, affordability and reliable delivery as well as the underlying demand for care.
How does Eli Lilly make money?
Lilly earns from prescription drug sales to wholesalers, healthcare providers and government systems. Reported revenue is reduced by rebates, discounts and other payments, especially in the United States. Margins depend on patient or member mix, reimbursement, supply costs and investment in future products, not simply on headline demand.
What drives Eli Lilly share price?
Lilly shares are driven by prescription growth, manufacturing capacity, clinical data, regulatory approvals, pricing and patent life. Expectations for obesity and diabetes medicines are especially important to valuation. The market usually looks several quarters ahead, so even a modest change in expected growth, margins or cash generation can have a large valuation effect.
What are the key revenue drivers for Eli Lilly?
Key drivers include patient adoption of incretin-based treatments, new indications, international launches and supply expansion. Oncology, immunology and neuroscience products diversify the portfolio. Volume growth should be considered alongside pricing, supply capacity and geographic launch or contract timing, all of which can make reported growth uneven.
What could drive long-term value for Eli Lilly?
Long-term value depends on converting research success into multiple durable franchises. Expanding manufacturing, demonstrating broader medical benefits and replenishing the pipeline are necessary to support growth beyond today's leading products. The strongest long-term result would combine wider patient access with productive innovation, reliable supply and enough pricing power to fund future growth.
| Organisation | Eli Lilly & Co |
| Headquarters | Lilly Corporate Center, Indianapolis, IN, United States, 46285 |
| Industry | Drug Manufacturers - General |
| CEO | Mr. David A. Ricks |
| E-voting on shares | Click here to vote |
Key Management of Eli Lilly & Co
Name | Title |
|---|---|
Mr. Jacob S. Van Naarden | Executive VP, President of Lilly Oncology & Head of Corporate Business Development |
Mr. Donald A. Zakrowski | Senior VP of Finance & Chief Accounting Officer |
Mr. Eric Dozier | Executive VP & Chief People Officer |
Mr. Ilya Yuffa | Executive VP and President of Lilly USA & Global Customer Capabilities |
Ms. Anat Hakim J.D. | Executive VP, General Counsel & Secretary |
Mr. Lucas E. Montarce | Executive VP & CFO |
Dr. Daniel M. Skovronsky M.D., Ph.D. | Chief Scientific & Product Officer and President of Lilly Research Laboratories |
Mr. Diogo Rau | Executive VP and Chief Information & Digital Officer |
Mr. Michael Czapar | Senior Vice President of Investor Relations |
Mr. David A. Ricks | Chairman, President & CEO |
FAQs
What is Eli Lilly & Co share price today?
Eli Lilly & Co share price today is $1,124.37 as on at the close of the market. Eli Lilly & Co share today touched a day high of $1,138.79 and a low of $1,119.00.
What is the 52 week high and 52 week low for Eli Lilly & Co share?
Eli Lilly & Co share touched a 52 week high of $1,292.65 on and a 52 week low of $712.05 on . Eli Lilly & Co stock price today i.e. is closed at $1,124.37,which is 13.02% down from its 52 week high and 57.91% up from its 52 week low.
What is Eli Lilly & Co's market capitalisation today?
Eli Lilly & Co market capitalisation is $1.08T as on .
How to invest in Eli Lilly & Co Stock (LLY) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for Eli Lilly & Co on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Eli Lilly & Co Shares that will get you 0.0013 shares as per Eli Lilly & Co share price of $1,124.37 per share as on September 10, 2026 at 1:29 am IST.
What is the minimum amount required to buy Eli Lilly & Co Stock (LLY) from India?
Indian investors can start investing in Eli Lilly & Co (LLY) shares with as little as ₹95.105 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹951.05 in Eli Lilly & Co stock (as per the Rupee-Dollar exchange rate as on ).
Based on Eli Lilly & Co share’s latest price of $1,124.37 as on September 10, 2026 at 1:29 am IST, you will get 0.0089 shares of Eli Lilly & Co. Learn more about
fractional shares .
What are the returns that Eli Lilly & Co has given to Indian investors in the last 5 years?
Eli Lilly & Co stock has given 368.3% share price returns and 28.48% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?